MWG in Talks with Potential Buyers for Units, But Will IP Issues Scuttle a Deal? | GenomeWeb

MWG Biotech is in discussions with several potential buyers for its Genomic Diagnosis and Genomic Technology units and still expects to complete a sale by the end of the year, MWG CEO Wolfgang Pieken told BioArray News this week.

“The interest in both of those businesses exceeded our expectations,” Pieken said. But he declined to name any of the firms that MWG is negotiating with for the businesses.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.